Optimal dose of Ligustrazine nanoparticles in a rat model of experimental peritoneal adhesion / 中国组织工程研究

ABSTRACT

BACKGROUND:Ligustrazine can effectively prevent and treat peritoneal adhesion and adhesive ileus after surgical treatment. OBJECTIVE:To prepare Ligustrazine nanoparticle spray which is prepared to achieve sustained release and improve clinical efficacy and to explore its optimal dose for preventing experimental peritoneal adhesions in rats. METHODS:Eighty rats were randomly divided into five groupsmodel group, sodium hyaluronate group, high-, medium-and low-dose Ligustrazine nanoparticle groups, with 16 rats in each group. After peritoneal adhesion model was established with rasp method, model group was immediately subject to abdomen-closing, while sodium hyaluronate group and Ligustrazine nanoparticle groups received sodium hyaluronate smearing and Ligustrazine nanoparticle spray (2.5, 5, 10 mg/kg), respectively. Al rats were kil ed at 1 and 2 weeks after modeling, to observe adhesions. The adhesion score was recorded. The adhesive tissue sections were stained with hematoxylin-eosin for pathological changes. The level of transformation growth factor-β1 in peritoneal fluid of rats was detected with ELISA assay. RESULTS AND CONCLUSION:Ligustrazine Nanoparticle spray had a sustained release effect, and prolonged the duration of action of drugs, thus achieving a better anti-adhesion effect post-surgery. The medium-and high-dose Ligustrazine nanoparticle sprays exhibited better anti-adhesion effects, and improved the rise of transformation growth factor-β1 level in the peritoneal fluid. As the drug concentration is low, the intraperitoneal administration in a spray manner is preferred. Because the total dose is limited, we define the optimal effective dose as 5 mg/kg.